Second- and third-generation aromatase inhibitors as first-line endocrine therapy in postmenopausal metastatic breast cancer patients: a pooled analysis of the randomised trials

The purpose of this study was to estimate in all randomised trials the relative risk of overall response rate (ORR), clinical benefit (CB), time to progression (TTP), overall survival (OS), and toxicity of aromatase inhibitors (AI), compared with tamoxifen (Tam) as first-line endocrine therapy in po...

Descripción completa

Detalles Bibliográficos
Autores principales: Ferretti, G, Bria, E, Giannarelli, D, Felici, A, Papaldo, P, Fabi, A, Di Cosimo, S, Ruggeri, E M, Milella, M, Ciccarese, M, Cecere, F L, Gelibter, A, Nuzzo, C, Cognetti, F, Terzoli, E, Carlini, P
Formato: Texto
Lenguaje:English
Publicado: Nature Publishing Group 2006
Materias:
Clinical Study
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2361349/
https://www.ncbi.nlm.nih.gov/pubmed/16736002
http://dx.doi.org/10.1038/sj.bjc.6603194

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2361349/
https://www.ncbi.nlm.nih.gov/pubmed/16736002
http://dx.doi.org/10.1038/sj.bjc.6603194

Ejemplares similares